Difference between revisions of "The Future of R&D in Pharmaceutical Industry in 2025"

From ScenarioThinking
Jump to navigation Jump to search
Line 18: Line 18:
Big pharma companies won't be anymore, and a whole scale of specialised smaller R&D companies will emerge
Big pharma companies won't be anymore, and a whole scale of specialised smaller R&D companies will emerge
<br><br>
<br><br>
[[Different focus in pharma R&D from cure to prevention]]<br>
[[Pharma R&D: from cure to prevention]]<br>
R&D of pharma will go to put part of its focus on establishing health claims for preventative formulations, like neutraceuticals and supplements
R&D of pharma will go to put part of its focus on establishing health claims for preventative formulations, like food, neutraceuticals and supplements
<br><br>
<br><br>
[[Alternative Healthcare system reform]]<br>
[[Alternative Healthcare system reform]]<br>

Revision as of 18:24, 13 October 2009

EMBA09 team:
Murat Akguc
Ruth Donners
Peter Friedl
Susan Liu

Work under construction. In case you have any questions, additions or comments, please do not edit these pages, but you are more than welcome to contact us.

Scenarios.

Below the 4 developed scenario's can be found, just click on the link to get the full description.

Cocktail bar: personalised medicine
Selfcare scenario, with personalised medicine and focus on prevention, mainly driven by ageing population

Healthcare system reform
Scenario wherein the healthcare system is more integrated, shorter lines between pharma, medicine, insurance companies

Pharma Valley
Big pharma companies won't be anymore, and a whole scale of specialised smaller R&D companies will emerge

Pharma R&D: from cure to prevention
R&D of pharma will go to put part of its focus on establishing health claims for preventative formulations, like food, neutraceuticals and supplements

Alternative Healthcare system reform
Scenario wherein the healthcare system is more integrated, shorter lines between pharma, medicine, insurance companies

Research Questions.

  • Will the system of blockbusters continue? Ie. no more blockbusters in the future, even focus on generics, or are there still enough other diseases to cure with one type of drug or without simply incrementally improving existing drugs?
  • Move to emerging markets (subquestions: what is government stance, how is local infrastructure (ie. can you get the drugs to the people?)?
  • What are regulatory issues regarding local registration of the drug?
  • Will medicine stay a mass product or will personalised medicines become prevalent?
  • Will pharmaceutical industry as it is today stay profitable?
  • Is there going to be a breakthrough in health?
  • Will preventative measures be implemented instead of current focus on care once ill?
  • Will pharma R&D stay consolidated or become more fragmented?
  • Will there be structural reform in health industry?
  • Will pharma industry become less technology push and more market pull?
  • Generics vs. Patents? What will the IP landscape be?

Driving forces.

Edited existing ones

Increasing potential to grow based on new available technology
Struggling old world economy
Increasing Empowerment of Consumers in Healthcare System
Continuously growing demand for new medical applications
The increasing gap between developed, emerging and poor economies
The increasing globalization of markets
Power of the United Nations
Legal Restrictions for Biotech increasing in certain countries, decreasing in others


Added new ones

IP rights
Logistics/Distribution
Illnesses of global importance/Pandemics
Research budget in pharmaceutical industry
Effect of development of health care system in emerging market countries to existing pharmaceutical industry
Unification of regulatory approval
Increasing Competitiveness through innovation in biotechnology
Changing business models for pharmaceutical industry


Resources